Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

OCUL – Ocular Therapeutix, Inc.

Float Short %

8.83

Margin Of Safety %

Put/Call OI Ratio

0.12

EPS Next Q Diff

0.01

EPS Last/This Y

-0.27

EPS This/Next Y

0.12

Price

12.29

Target Price

17.5

Analyst Recom

1.08

Performance Q

70.48

Relative Volume

0.6

Beta

1.5

Ticker: OCUL




21 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-07-25OCUL12.210.130.0438641
2025-07-28OCUL12.090.130.0538970
2025-07-29OCUL11.770.131.3439166
2025-07-30OCUL11.650.150.0139173
2025-07-31OCUL11.570.151.4239059
2025-08-01OCUL11.910.150.0639178
2025-08-04OCUL12.350.140.6140345
2025-08-05OCUL11.990.180.0141360
2025-08-06OCUL12.480.160.0345841
2025-08-07OCUL12.30.150.0147698
2025-08-08OCUL12.20.150.0048695
2025-08-11OCUL12.560.150.0249565
2025-08-12OCUL12.480.150.0550275
2025-08-13OCUL12.490.150.5350069
2025-08-14OCUL12.640.150.0449741
2025-08-15OCUL12.620.150.0349811
2025-08-18OCUL12.30.111.0644865
2025-08-19OCUL12.150.120.0445185
2025-08-20OCUL11.960.120.0945381
2025-08-21OCUL12.120.120.1345391
2025-08-22OCUL12.30.120.0045454
DateSymbolLastP/C OIP/C VolTotal OI
21 items Current Page1 of 1




21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-07-25OCUL12.21-36.5- -1.45
2025-07-28OCUL12.06-36.5- -1.45
2025-07-29OCUL11.75-36.5- -1.45
2025-07-30OCUL11.66-36.5- -1.45
2025-07-31OCUL11.58-36.5- -1.45
2025-08-01OCUL11.92-36.5- -1.45
2025-08-04OCUL12.35-36.5- -1.45
2025-08-05OCUL12.00-36.5- -1.45
2025-08-06OCUL12.50-36.5- -1.45
2025-08-07OCUL12.30-71.8- -1.45
2025-08-08OCUL12.21-71.8- -1.50
2025-08-11OCUL12.55-70.4- -1.49
2025-08-12OCUL12.48-70.4- -1.49
2025-08-13OCUL12.50-70.4- -1.49
2025-08-14OCUL12.64-70.4- -1.49
2025-08-15OCUL12.63-70.4- -1.49
2025-08-18OCUL12.30-70.4- -1.49
2025-08-19OCUL12.14-70.4- -1.49
2025-08-20OCUL11.95-70.4- -1.49
2025-08-21OCUL12.12-70.4- -1.49
2025-08-22OCUL12.29-70.4- -1.49
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1




21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-07-25OCUL-0.3121.6511.10
2025-07-28OCUL-0.3121.1011.10
2025-07-29OCUL-0.3121.1011.10
2025-07-30OCUL-0.3121.1011.10
2025-07-31OCUL-0.3121.1011.10
2025-08-01OCUL-0.3121.1011.10
2025-08-04OCUL-0.3121.4611.10
2025-08-05OCUL-0.2421.4611.10
2025-08-06OCUL-0.2421.4611.10
2025-08-07OCUL-0.2421.4611.10
2025-08-08OCUL-0.2221.4610.16
2025-08-11OCUL-0.2219.3010.17
2025-08-12OCUL-0.2219.308.82
2025-08-13OCUL-0.2219.308.82
2025-08-14OCUL-0.2219.308.82
2025-08-15OCUL-0.2219.308.82
2025-08-18OCUL-0.2218.698.82
2025-08-19OCUL-0.2218.698.82
2025-08-20OCUL-0.2218.698.82
2025-08-21OCUL-0.2218.698.83
2025-08-22OCUL-0.2218.698.83
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS

-0.39

Avg. EPS Est. Current Quarter

-0.38

Avg. EPS Est. Next Quarter

-0.38

Insider Transactions

-0.22

Institutional Transactions

18.69

Beta

1.5

Average Sales Estimate Current Quarter

14

Average Sales Estimate Next Quarter

16

Fair Value

Quality Score

40

Growth Score

40

Sentiment Score

72

Actual DrawDown %

49.4

Max Drawdown 5-Year %

-90.9

Target Price

17.5

P/E

Forward P/E

PEG

P/S

37.77

P/B

6.95

P/Free Cash Flow

EPS

-1.28

Average EPS Est. Cur. Y​

-1.49

EPS Next Y. (Est.)

-1.37

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-382.51

Relative Volume

0.6

Return on Equity vs Sector %

-95.5

Return on Equity vs Industry %

-82.6

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.04

EBIT Estimation

Ocular Therapeutix, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 274
Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing AXPAXLI, an axitinib intravitreal hydrogel that is in phase 3 clinical trials for the treatment of wet age-related macular degeneration and in Phase 1 clinical trials for the treatment of non-proliferative diabetic retinopathy; PAXTRAVA, a travoprost intracameral hydrogel, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension. The company has a license agreement and collaboration with AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and PAXTRAVA. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
stock quote shares OCUL – Ocular Therapeutix, Inc. Stock Price stock today
news today OCUL – Ocular Therapeutix, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch OCUL – Ocular Therapeutix, Inc. yahoo finance google finance
stock history OCUL – Ocular Therapeutix, Inc. invest stock market
stock prices OCUL premarket after hours
ticker OCUL fair value insiders trading